ADPGK and neoplasm: The recent demonstration of the diversion of glycolytic flux by ADPGK to hyper-reduce ubiquinone and drive mitochondrial generation of ROS, in response to T-cell receptor signaling, also raises the possibility that ADPGK might contribute to elevated ROS production in some tumour cells.